HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /
2024-04-26 9:03:20 AM | Chg. -0.030 | Volume | Bid9:03:20 AM | Ask10:03:20 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
3.000EUR | -0.99% | 2,447 Turnover: 7,384.960 |
2.970Bid Size: 1,397 | 3.000Ask Size: 1,288 | 102.53 mill.EUR | 0.00% | - |
GlobeNewswire
2017-11-16
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-02-05
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
2006-10-09
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients